Patents by Inventor Brett D. MENSH

Brett D. MENSH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190083011
    Abstract: Methods and devices for the diagnosis and treatment of diabetes are disclosed in which an analyte concentration within a peritoneal fluid of a human subject may be determined by implanting an analyte sensor apparatus in the subject where the apparatus may comprise a housing and a flexible sensing catheter which has a lumen with a plurality of apertures and an exterior surface with an analyte sensor affixed thereto. The catheter may comprise a proximal end attached to the housing and the remaining end may be positioned freely within the peritoneal space to contact peritoneal fluid where an analyte concentration in the peritoneal fluid may be sensed. The housing may be anchored at a subcutaneous site proximate the peritoneal space. The sensed analyte concentration may then be transduced into a transmittable electrical signal.
    Type: Application
    Filed: October 19, 2018
    Publication date: March 21, 2019
    Applicant: TheraNova, LLC
    Inventors: Daniel R. BURNETT, Evan S. LUXON, Marcie HAMILTON, Brian M. NEIL, Brett D. MENSH
  • Patent number: 10143408
    Abstract: Methods and devices for the diagnosis and treatment of diabetes are disclosed in which an analyte concentration within a peritoneal fluid of a human subject may be determined by implanting an analyte sensor apparatus in the subject where the apparatus may comprise a housing and a flexible sensing catheter which has a lumen with a plurality of apertures and an exterior surface with an analyte sensor affixed thereto. The catheter may comprise a proximal end attached to the housing and the remaining end may be positioned freely within the peritoneal space to contact peritoneal fluid where an analyte concentration in the peritoneal fluid may be sensed. The housing may be anchored at a subcutaneous site proximate the peritoneal space. The sensed analyte concentration may then be transduced into a transmittable electrical signal.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: December 4, 2018
    Assignee: TheraNova, LLC
    Inventors: Daniel R. Burnett, Evan S. Luxon, Marcie Hamilton, Brian M. Neil, Brett D. Mensh
  • Publication number: 20170172469
    Abstract: Methods and devices for the diagnosis and treatment of diabetes are disclosed in which an analyte concentration within a peritoneal fluid of a human subject may be determined by implanting an analyte sensor apparatus in the subject where the apparatus may comprise a housing and a flexible sensing catheter which has a lumen with a plurality of apertures and an exterior surface with an analyte sensor affixed thereto. The catheter may comprise a proximal end attached to the housing and the remaining end may be positioned freely within the peritoneal space to contact peritoneal fluid where an analyte concentration in the peritoneal fluid may be sensed. The housing may be anchored at a subcutaneous site proximate the peritoneal space. The sensed analyte concentration may then be transduced into a transmittable electrical signal.
    Type: Application
    Filed: March 6, 2017
    Publication date: June 22, 2017
    Applicant: TheraNova, LLC
    Inventors: Daniel R. BURNETT, Evan S. LUXON, Marcie HAMILTON, Brian M. NEIL, Brett D. MENSH
  • Patent number: 9603558
    Abstract: Methods and devices for the diagnosis and treatment of diabetes are disclosed in which an analyte concentration within a peritoneal fluid of a human subject may be determined by implanting an analyte sensor apparatus in the subject where the apparatus may comprise a housing and a flexible sensing catheter which has a lumen with a plurality of apertures and an exterior surface with an analyte sensor affixed thereto. The catheter may comprise a proximal end attached to the housing and the remaining end may be positioned freely within the peritoneal space to contact peritoneal fluid where an analyte concentration in the peritoneal fluid may be sensed. The housing may be anchored at a subcutaneous site proximate the peritoneal space. The sensed analyte concentration may then be transduced into a transmittable electrical signal.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: March 28, 2017
    Assignee: TheraNova, LLC
    Inventors: Daniel R. Burnett, Evan S. Luxon, Marcie Hamilton, Brian M. Neil, Brett D. Mensh
  • Publication number: 20150011855
    Abstract: Methods and devices for the diagnosis and treatment of diabetes are disclosed in which an analyte concentration within a peritoneal fluid of a human subject may be determined by implanting an analyte sensor apparatus in the subject where the apparatus may comprise a housing and a flexible sensing catheter which has a lumen with a plurality of apertures and an exterior surface with an analyte sensor affixed thereto. The catheter may comprise a proximal end attached to the housing and the remaining end may be positioned freely within the peritoneal space to contact peritoneal fluid where an analyte concentration in the peritoneal fluid may be sensed. The housing may be anchored at a subcutaneous site proximate the peritoneal space. The sensed analyte concentration may then be transduced into a transmittable electrical signal.
    Type: Application
    Filed: June 12, 2014
    Publication date: January 8, 2015
    Applicant: THERANOVA, LLC
    Inventors: Daniel R. BURNETT, Evan S. LUXON, Marcie HAMILTON, Brian M. NEIL, Brett D. MENSH